People · Operator
Named in public records as an officer, director or promoter · active 2010–2026 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avalyn Pharma Inc. | — | Biotechnology | Series D+ | $244.0M | $2.7B | 2023 |
| Alpine Immune Sciences, Inc. | — | Biotechnology | Series C | $234.9M | $2.3B | 2014 |
| Larimar Therapeutics, Inc. | — | Biotechnology | Series C | $201.0M | $3.3B | 2020 |
| Mirum Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $138.5M | $347.9M | 2018 |
| Audentes Therapeutics, Inc. | — | Biotechnology | Series C | $107.5M | $2.7B | 2014 |
| BiomX Inc. | — | Pharmaceuticals | Series C | $72.3M | $16.9M | 2024 |
| ARS Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $63.0M | $1.3B | 2018 |
| Chondrial Therapeutics Holdings, Llc | — | Biotechnology | Series B | $44.2M | $595.0M | 2016 |
| Rib X Pharmaceuticals Inc | — | Pharmaceuticals | Series B | $29.7M | $635.4M | 2010 |
| Elion Therapeutics, Inc. | — | Biotechnology | Series B | $25.4M | $185.6M | 2024 |
| Innervace, Inc. | — | Biotechnology | Series A | $10.0M | $131.0M | 2022 |
Jonathan Leff at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jonathan Leff on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Tiba Aynechi | 2 | 9 |
| David Miller | 1 | 29 |
| Peter Barrett | 1 | 18 |
| Bruce Booth | 1 | 12 |
| John Moore | 1 | 12 |
| Patrick Heron | 1 | 11 |
| Ed Mathers | 1 | 11 |
| Jonathan Silverstein | 1 | 10 |
| Michael Grey | 1 | 10 |
| Kush Parmar | 1 | 10 |
| Ketan Patel | 1 | 10 |
| Peter Kolchinsky | 1 | 8 |
| Rajeev Dadoo | 1 | 7 |
| Mitchell S. Bloom | 1 | 7 |
| Niall O'Donnell | 1 | 7 |
| PAUL SEKHRI | 1 | 7 |
| Patrick J. Heron | 1 | 7 |
| Thomas Woiwode | 1 | 7 |
| Harry H Penner, Jr. | 1 | 6 |
| Mitchell Bloom | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.